SMO and medulloblastoma: Loss of PTCH1 is associated with ~70% of BCCs and 45% of SHH-subtyped medulloblastomas whereas the SMO mutations (such as the constitutively active SMO-M2 [W535L) mutation] is less frequently found in these diseases4,5.